糖类抗原15—3、癌胚抗原、环氧合酶-2联合检测在乳腺癌诊断中的应用

Application of combination detection of CA15-3, CEA, COX-2 on diagnosis of breast carcinoma

目的 探讨糖类抗原15-3（CA15-3）、癌胚抗原（CEA）、环氧合酶-2（COX-2）联合检测对乳腺癌早期诊断的应用价值。方法 选择经影像学和病理学诊断为乳腺癌患者53例，同时选择同期良性乳腺病患者61例及同期健康体检者68名，采用电化学发光技术与酶联免疫吸附法（ELISA）分别检测血清CA15-3、CEA、COX-2水平。结果 乳腺癌组CA15-3、CEA、COX-2血清水平分别为（34.67±13.20）U／ml、（7.38±3.87）ng／ml、（43.25±10.87）ng／ml，与良性乳腺病组和健康对照组血清含量比较差异具有统计学意义（均P＜0.01）；CA15-3、CEA、COX-2联合检测将各项指标单独检测的阳性检出率提高至84.9 %（45／53），其敏感度提高至84.9 %，准确度提高至91.2 %。结论 三项肿瘤标志物联合应用能弥补单项肿瘤标志物临床应用的不足，对提高乳腺癌阳性检出率具有一定意义。

Objective To investigate the value of combination detection of CA15-3, CEA, COX-2 on early diagnosis of breast carcinoma. Methods 68 breast cancer patients, 61 benign breast disease patients and 68 healthies were selected. Serum levels of COX-2 were detected by ELISA technique, CA15-3 and CEA levels were detected by electroche-miluminescence technique. Results Serum levels of CA15-3, CEA, COX-2 in breast carcinoma group were （34.67±13.20） U/ml, （7.38±3.87） ng/ml, （43.25±10.87） ng/ml. Their levels were higher than those in benign breast disease group and healthy group, the differences were significant （P 〈 0.01）. In combination detection, the sensitivity was 84.9 %, and accuracy was 91.2 %, which were higher than single tumor marker used in breast cancer diagnosis. Conclusion The combined detection of CA15-3, CEA, COX-2 could increase the diagnosis rate of breast carcinoma.